Abstract Library

#3930 Gender role in the authorship of Italian academic medical literature on neuroendocrine neoplasms: Cliché or reality?

Introduction: There is an increasing attention to gender equality in the medical setting. While males have dominated the physician lines over the last decades the recent female doctors’ number increasing might reduce this gender gap. However, this may be not true in the academic area.

Conference:

Presenting Author: Rossi R

Authors: Rossi R, La Salvia A, Modica R, Spada F,

Keywords: gender gap, gender equality, neuroendocrine literature, academic setting,

#3799 High-dose somatostatin analogues’ effects on glycolipid metabolism in patients with neuroendocrine tumors

Introduction: Somatostatin analogues (SSAs), octreotide and lanreotide, represent the cornerstone medical therapy of both sporadic and hereditary G1-G2 neuroendocrine tumors (NETs). Changes in glucose metabolism have been shown to occur during standard-dose SSA therapy, but no changes during high-dose therapy have been evaluated.

Conference:

Presenting Author:

Authors: Liccardi A, Minotta R, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, somatostatin analogues, lipid, hyperglycaemia, high dose SSA, glycolipid metabolism,

#3797 Evaluation of neutrophile to lymphocyte and platelet to lymphocyte ratio in patients with medullary thyroid cancer (MTC)

Introduction: Medullary thyroid cancer (MTC) is a rare neoplasm in which the investigation of new biomarkers is essential. An elevated neutrophile to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has been proposed as a negative prognostic factor in several neoplasms, but their role in MTC is unclear.

Conference:

Presenting Author:

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, biomarker, medullary thyroid carcinoma, mtc, nlr, plr,

#3782 Somatostatin analogues (SSA) in gastroenteropancreatic neuroendocrine tumors (GEP-NET) – Impact on glycemia and lipid profile in a monocentric series

Introduction: Somatostatin analogues (SSA) are often the first line therapy in neuroendocrine tumors (NET). The management of hyperglycaemia and dyslipidaemia are one of the most important challenges in healthcare. The impact of SSA on metabolic profile in GEP-NET is highly debated.

Conference:

Presenting Author: Cannavale G

Authors: Cannavale G, Benevento E, Minotta R, Liccardi A, Modica R,

Keywords: SSA, lipid profile, glycemia, GEP-NET, hyperglycaemia, Somatostatin analogues,

#3767 Metabolic alterations in patients with pheochromocytoma/paragangliomas and SDHB mutations

Introduction: Pheochromocytoma/paragangliomas (PPGL) patients with SDHB mutation may have unfavourable course of disease. SDHB gene inactivation results in up-regulation of glycolytic reaction and activation of pseudo-hypoxic phenotype in preclinical studies.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Cannavale G, Liccardi A, Minotta R, Modica R,

Keywords: pheochromocytoma, paraganglioma, SDHB,